The logics of leukocytapheresis as a natural biological therapy for inflammatory bowel disease

Expert Opinion on Biological Therapy

Volumn 6, Issue 5, 2006, Pages 453-466

  Kanai, Takanori ^a   Hibi, Toshifumi ^b   Watanabe, Mamoru ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b KEIO UNIVERSITY   (Japan)

Author keywords

Biological therapy; Granulocytes; Inflammatory bowel disease; Leukocytapheresis; Lymphocytes; Monocytes; Ulcerative colitis

Indexed keywords

ADALIMUMAB; BASILIXIMAB; DACLIZUMAB; EPIDERMAL GROWTH FACTOR; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 6; KERATINOCYTE GROWTH FACTOR; TUMOR NECROSIS FACTOR ALPHA;

BIOLOGICAL THERAPY; CENTRIFUGATION; COLON RESECTION; CYTAPHERESIS; DRUG EFFICACY; DRUG SAFETY; ENTERITIS; GRANULOCYTE; HUMAN; IMMUNOMODULATION; LEUKOCYTE; MACROPHAGE; MONOCYTE; PERIPHERAL LYMPHOCYTE; REVIEW;

ADSORPTION; ANTIBODIES, MONOCLONAL; CENTRIFUGATION; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATORY BOWEL DISEASES; LEUKAPHERESIS; LEUKOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33646571241     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.6.5.453     Document Type: Review

References (110)

1. ALLISON MC, DHILLON AP, LEWIS WG, POUNDER RE: Inflammatory Bowel Disease. Allison MC, Dhillon AP, Lewis WG, Pounder RE (Eds), Mosby, London, UK (1998):9-95. • This book is rich in endoscopic and biopsy illustrations.
2. FIOCCHI C: Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology (1998) 115:182-205.
3. PODOLSKY DK: Inflammatory bowel disease. N. Engl J. Med. (2002) 347:417-429
4. HARRIS ML, BAYLESS TM: Dietary antigens as aggravating factors in Crohn's disease. Dig. Dis. Sci. (1989) 34:1613-1614.
5. SHANAHAN F: Crohn's disease. Lancet (2002) 359:62-69.
6. SARTOR RB: Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases. Am. J. Gastroenterol. (1997) 92(Suppl.):5S-11S.
7. TAFFET SL, DAS KM: Sulphasalazine-adverse effects and desensitization. Dig. Dis. Sci. (1983) 28:833-842.
8. PRESENT DH: How to do without steroids in inflammatory bowel disease. Inflamm. Bowel Dis. (2000) 6:48-57. • This paper is a critical review on the limitations of corticosteroid therapy in IBD.
9. RACHMILEWITZ D: Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis. (On behalf of an international study group). Br. Med. J. (1989) 298:82-86.
10. KORNBLUTH A, MARION JF, SALOMON P, JANOWITZ HD: How effective is current medical therapy for severe ulcerative colitis? J. Clin. Gastroenterol. (1995) 20:280-284.
11. TRUELOVE SC, JEWELL DP: Intensive intravenous regimens for severe attacks of ulcerative colitis. Lancet (1974) 1:1067-1070. • This is a first report of intensive corticosteroid therapy for UC.
12. JARNEROT G, ROLNY P, SANDBERG-GERTZEN H: Intensive intravenous treatment of ulcerative colitis. Gastroenterology (1985) 89:1005-1013.
13. HANAUER SB: Medical therapy of ulcerative colitis. Gastroenterology (2004) 126:1582-1592.
14. O'KEEFE SJ: Nutrition and gastrointestinal disease. Scand. J. Gastroenterol. (1996) 220(Suppl.):52-59.
15. HYDE GM, THILLAINAYAGAM AV, JEWELL DP: Intravenous cyclosporin as rescue therapy in severe ulcerative colitis: time for a reappraisal? Eur. J. Gastroenterol. Hepatol. (1998) 10:411-413.
16. HANAUER SB: Can cyclosporine go it alone in severe ulcerative colitis. Curr. Gastroenterol. Rep. (2001) 3:455-456.
17. SERKOVA NJ, CHRISTIANS U, BENET LZ: Biochemical mechanisms of cyclosporine neurotoxicity. Mol. Interv. (2004) 4:97-107.
18. SCHREAIBER S, NIKOLAUS S, HAMPE J et al.: Tumour necrosis factor alpha and interleukin 1beta in relapse of Crohn's disease. Lancet (1999) 353:459-461. • One of the first reports directly implicating cytokines in the relapse of CD.
19. PAPADAKIS KA, TARGAN SR: Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu. Rev. Med. (2000) 51:289-298.
20. TARGAN SR, HANAUER SB, VAN DEVENTER SJ: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N. Engl. J. Med. (1997) 337:1029-1035.
21. HANAUER SB, FEAGAN BG, LICHTENSTEIN GR: Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet (2002) 359:1541-1549.
22. RUTGEERTS P, SANDBORN WJ, FEAGAN BG et al.: Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med.. (2005) 353:2462-2476.
23. KORZENIK JR, PODOLSKY DK: Evolving knowledge and therapy of inflammatory bowel disease. Nat. Rev. Drug Discov. (2006) 5:197-209.
24. EVANS RC, CLARKE L, HEATH P, STEPHENS S, MORRIS AI, RHODES JM: Treatment of ulcerative colitis with an engineered human anti-TNF-alpha antibody CDP571. Aliment. Pharmacol. Ther. (1997) 11:1031-1035.
25. IYER S, KONTOYIANNIS D, CHEVRIER D et al.: Inhibition of tumor necrosis factor mRNA translation by a rationally designed immunomodulatory peptide. J. Biol. Chem. (2000) 275:17051-17057.
26. TRAVIS S, YAP L, HAWKEY CJ: Novel and effective therapy for ulcerative colitis: results of parallel, prospective, placebo-controlled trials (abstr). Am. J. Gastroenterol. (2003) 98:S239.
27. GORDON FH, HAMILTON MI, DONOGHUE S et al.: A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin. Aliment. Pharmacol. Ther. (2002) 16:699-705.
28. FEAGAN B, GREENBERG GR, WILD G: A randomized controlled trial of a humanized alpha4beta7 antibody in ulcerative colitis (abstr). Am. J. Gastroenterol. (2003) 98:S248-S249.
29. SANDBORN WJ, COLOMBEL JF, ENNS R, FEAGAN BG, HANAUER SB: Natalizumab induction and maintenance therapy for Crohn's disease. N. Engl. J. Med. (2005) 353:1912-1925. •• This paper reports death from progressive multifocal leukoencephalopathy, associated with the JC virus in the natalizumab group.
30. VAN ASSCHE G, DALLE I, NOMAN M et al.: A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis. Am. J. Gastroenterol. (2003) 98:369-376.
31. TILG H, VOGELSANG H, LUDWICZEK O: A randomized placebo-controlled trial of pegylated interferon alpha in active ulcerative colitis (abstr). Gastroenterology (2003) 124:A62.
32. BECK PL, PODOLSKY DK: Growth factors in inflammatory bowel disease. Inflamm. Bowel Dis. (1999) 5:44-60.
33. SANDBORN WJ, SANDS BE, WOLF DC et al.: Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Aliment. Pharmacol. Ther. (2003) 17:1355-1364.
34. DEVOS SA, VAN DEN BOSSCHE N, DE VOS M, NAEYAERT JM: Adverse skin reactions to anti-TNF-α. Dermatology (2003) 206:388-390.
35. SEEGERS D, BOUMA G, PENA AS: Review article: a critical approach to new forms of treatment of Crohn's disease and ulcerative colitis. Aliment. Pharmacol. Ther. (2002) 16(Suppl. 4):53-58.
36. GOMEZ-REINO JJ, CARMONA L, VALVERDE VR, MOLA EM, MONTERO MD: Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. BIOBADASER Group. Arthritis Rheum. (2003) 48:2122-2127.
37. KROESEN S, WIDMER AF, TYNDALL A, HASLER P: Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology (2003) 42:617-621.
38. BROWN SL, GREENE MH, GERSHON SK, EDWARDS ET, BRAUN MM: Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum. (2002) 46:3151-3158.
39. ATZENI A, ARDIZZONE S, SARZI-PUTTINI P et al.: Autoantibody profile during short-term infliximab treatment for Crohn's disease: a prospective cohort study. Aliment. Pharmacol. Ther. (2005) 22:453-461.
40. TIBBLE JA, SIGTHORSSON G, BRIDGER D, FAGERHOL MK, BJARNASON I: Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology (2000) 119:15-22. •• This is the first major report on the use of faecal neutrophil protein (calprotectin) as a biomarker of relapse in both UC and CD.
41. LIMBURG P, DAVID M, AHLQUIST A, SANDBORN WJ: Faecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhoea referred for colonoscopy. Am. J. Gastroenterol. (2000) 95:2831-2837.
42. ROSETH AG, SCHMIDT PN, FAGERHOL MK: Correlation between faecal excretion of Indium-111-labelled granulocytes and calprotectin, a granulocyte marker. Scand. J. Gastroenterol. (1999) 34:50-54.
43. CASSATELLA MA: The production of cytokines by polymorphonuclear neutrophils. Immunol. Today (1995) 16:21-26.
44. NIKOLAUS S, BAUDITZ J, GIONCHETTI P: Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin-10 during intestinal inflammation. Gut (1998) 42:470-476.
45. MCCARTHY DA, RAMPTON DS, LIU YC: Peripheral blood neutrophils in inflammatory bowel disease: morphological evidence of in vivo activation in active disease. Clin. Exp. Immunol. (1991) 86:489-493.
46. MAHIDA YR: The key role of macrophages in the immunopathogenesis of inflammatory bowel disease. Inflamm. Bowel Dis. (2000) 6:21-33.
47. HANAI H, WATANABE F, SANIABADI A, MATSUSHITA I, TAKEUCHI K, IIDA T: Therapeutic efficacy of granulocyte and monocyte adsorption apheresis in severe active ulcerative colitis. Dig. Dis. Sci. (2002) 47:2349-2353.
48. HANAI H, WATANABE F, TAKEUCHI K, SANIABADI A, BJARNASON I: Leukcocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective uncontrolled pilot study. Clin. Gastroenterol. Hepatol. (2003) 1:28-35. •• This is the first major study on the efficacy of selective leukocytapheresis in patients with severe steroid-refractory UC.
49. SANIABADI AR, HANAI H, BJARNASON I, LOFBERG R: Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes. Ther. Apher. Dial. (2003) 7:48-59.
50. RUGTVEIT J, BRANDTZAEG P, HALSTENSEN TS, FAUSA O, SCOTT H: Increased macrophage subsets in inflammatory bowel disease: apparent recruitment from peripheral blood monocytes. Gut (1994) 35:669-674.
51. MEURET G, BITZI A, HAMMER B: Macrophage turnover in Crohn's disease and ulcerative colitis. Gastroenterology (1978) 74:501-503.
52. BRANNIGAN AE, O'CONNELL PR, HURLEY H: Neutrophil apoptosis is delayed in patients with inflammatory bowel disease. Shock (2000) 13:361-366.
53. MEAGHER LC, COUSIN JM, SECKL JR, HASLETT C: Opposing effects of glucocorticoids on the rate of appoptosis in neutrophilic and eosinophilic granulocytes. J. Immunol. (1996) 156:4422-4428.
54. GRISHAM MB, YAMADA T: Neutrophils, nitrogen oxides and inflammatory bowel disease, neuro-immuno-physiology of the gastrointertinal mucosa. Ann. NY Acad. Sci. (1992) 664:103-115. •• This paper is an excellent source of review and analysis of the mechanisms by which neutrophils contribute to mucosal tissue injury in IBD.
55. MORSE EE, CARBONE PP, FREIREICH EJ, BRONSON W, KLIMAN A: Repeated leukapheresis of patients with chronic myelocytic leukemia. Transfusion (1966) 6:175-182.
56. BUCKNER D, GRAW RG JR, EISEL RJ, HENDERSON ES, PERRY S: Leukapheresis by continous flow centrifugation (CFC) in patients with chronic myelocytic leukemia (CML). Blood (1969) 33:353-369.
57. CURTIS JE, HERSH EM, FREIREICH EJ: Leukoapheresis therapy of chronic lymphocytic leukemia. Blood (1972) 39:163-175.
58. PEARSON CM, PAULUS HE, MACHLEDER HI: The role of the lymphocyte and its products in the propagation of joint disease. Ann. NY Acad. Sci. (1975) 256:150-168.
59. TENENBAUM J, UROWITZ MB, KEYSTONE EC, DWOSH IL, CURTIS JE: Leukoapheresis in severe rheumatoid arthritis. Ann. Rheum. Dis. (1979) 38:40-44.
60. BICKS RO, GROSHART KW, CHANDLER RW: The treatment of severe chronically active Crohn's disease by T8 (suppressor cell) lymphapheresis (Abstr). Gastroenterology (1985) 88:A1325.
61. BICKS RO, GROSHART KW, CHANDLER RW: The treatment of severe chronically active Crohn's disease by T lymphocyte apheresis (Abstr). Gastroenterology (1986) 90:A1346.
62. BICKS RO, GROSHART KW, LUTHER RW: Total parenteral nutrition (TPN) plus T-lymphocyte apheresis (TLA) in the treatment of severe chronic active Crohns disease (Abstr). Gastroenterology (1987) 94:A34.
63. LEREBOURS E, BUSSEL A, MODIGLIANI R et al.: Treatment of Crohn's disease by lymphocyte apheresis: a randomized controlled trial. Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology (1994) 107:357-361. •• This is the first controlled study showing lack of clinical benefit from selective lymphocytapheresis.
64. AYABE T, ASHIDA T, TANIGUCHI M et al.: A pilot study of centrifugal leukocyte apheresis for corticosteroid-resistant active ulcerative colitis. Intern. Med. (1997) 36:322-326.
65. AYABE T, ASHIDA T, KOHGO Y: Centrifugal leukocyte apheresis for ulcerative colitis. Ther. Apher. (1998) 2:125-128.
66. KOHGO Y, HIBI T, CHIBA T et al.: Leukocyte apheresis using a centrifugal cell separator in refractory ulcerative colitis; a multicenter open label trial. Study group for Alternative Therapies in Ulcerative Colitis Patients. Ther. Apher. (2002) 6:255-260.
67. HIRAISHI K, TAKEDA Y, SANIABADI A et al.: Studies on the mechanisms of leukocyte adhesion to cellulose acetate beads: an in vitro model to assess the efficacy of cellulose acetate carrier-based granulocyte and monocyte adsorptive apheresis. Ther. Apher. Dial. (2003) 7:334-340.
68. SANIABADI AR, HANAI H, SUZUKI Y, BJARNASON I, LOFBERG R: Adacolumn for selective leukocytapheresis as a non-pharmacological treatment for patients with disorders of the immune system: an adjunct or an alternative to drug therapy?. J. Clin. Apher. (2005) 20:171-184. • This paper is a comprehensive review on the application of selective leukocytapheresis to treat inflammatory diseases.
69. SHIMOYAMA T, SAWADA K, TANAKA T et al.: Granulocyte and monocyte apheresis with the G-1 column in the treatment of patients with active ulcerative colitis. Jpn. J. Apher. (1999) 18:117-131.
70. STACK WA, LONG RG, HAWKEY CJ: Short and long-term outcome of patients treated with cyclosporin for severe acute ulcerative colitis. Aliment. Pharmacol. Ther. (1998) 12:973-978.
71. KANKE K, NAKANO M, HIRAISHI H, TERANO A: Evaluation of granulocyte/monocyte apheresis therapy for active ulcerative colitis. Dig. Liv. Dis. (2004) 36:512-518.
72. NAGANUMA M, FUNAKOSHI S, SAKURABA K et al.: Granulocytapheresis is useful as an alternative therapy in patients with steroid-refractory or -dependent ulcerative colitis. Inflamm. Bowel Dis. (2004) 10:251-257.
73. YAMAMOTO T, UMEGAE S, KITAGAWA T, YASUDA Y, YAMADA Y, TAKAHASHI D: Granulocyte and monocyte adsorptive apheresis in the treatment of active distal ulcerative colitis: a prospective, pilot study. Aliment. Pharmacol. Ther. (2004) 20:783-792.
74. PREMCHAND P, TAKEUCHI K, BJARNASON I: Granulocyte, macrophage, monocyte apheresis for refractory ulcerative proctitis. Eur. J. Gastroenterol. Hepatol. (2004) 16:943-945.
75. DOMENECH E, HINOJOSA J, ESTEVE-COMAS M, GASSULL A: Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU). Granulocyteaphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study. Aliment. Pharmacol. Ther. (2004) 20:1347-1352.
76. SUZUKI Y, YOSHIMURA N, SANIABADI AR, SAITO Y: Selective neutrophil and monocyte adsorptive apheresis as a first line treatment for steroid naive patients with active ulcerative colitis: a prospective uncontrolled study. Dig. Dis. Sci. (2004) 49:565-571.
77. COHEN RD: Treating ulcerative colitis without medications - 'Look Mom, No Drugs!' Gastroenterology (2005) 128:235-236: • This is a good commentary on the use of selective leukocytapheresis instead of drug therapy.
78. MAIDEN L, BAUR R, TAKEUCHI K et al.: Adacolumn apheresis reduces relapse rates in patients at significant risk of clinical relapse (Abstr). Gut (2005) 54:A57.
79. MATSUI T, NISHIMURA T, MATAKE H, OHTA T, SAKURAI T, YAO T: Granulocytapheresis for Crohn's disease: a report on seven refractory patients. Am. J. Gastroenterol. (2003) 98:511-512.
80. FUKUDA Y, MATSUI T, SUZUKI Y, KANKE K, HIBI T: granulocyte and monocyte apheresis for refractory Crohn's disease: an open multicenter prospective study. J. Gastroenterol. (2004) 39:1158-1164.
81. MURATOV V, LUNDAHL J, ULFGREN AK et al.: Downregulation of interferon- parallels clinical response to selective leukocyte apheresis in patients with inflammatory bowel disease. A 12-month follow-up study. Int. J. Colorectal Dis. (2006) (In Press).
82. HANAI H, WATANABE F, SANIABADI A et al.: Correlation of serum soluble TNF-alpha receptors I and II levels with disease activity in patients with ulcerative colitis. Am. J. Gastroenterol. (2004) 99:1532-1538.
83. MOHLER KM, TORRANCE DS, SMITH GA, WIDMER MB: Soluble tumour necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoximia and function simultaneously as both TNF carriers and TNF antagonists. J. Immunol. (1993) 151:1548-1561.
84. KASHIWAGI N, HIRATA I, KASUKAWA R: A role for granulocyte and monocyte apheresis in the treatment of rheumatoid arthritis. Ther. Apher. (1998) 2:134-141
85. KASHIWAGI N, SANIABADI A, SHIMOYAMA T et al.: Immunomodulatory effects of granulocyte and monocyte adsorption apheresis as a treatment for patients with ulcerative colitis. Dig. Dig. Sci. (2002) 47:1334-1341.
86. BISWAS P, MANTELLI B, HASSON H, SANIABADI A, LAZZARIN A, BERETTA A: In vivo modulation of leukocyte trafficking receptor following therapeutic purging of myeloid cells: implications for treatment of HIV infection and other immune disorders. Clin. Immunol. (2003) 109:355-358.
87. TAKEDA Y, SHIOBARA N, SANIABADI AR, ADACHI M, HIRAISHI K: Adhesion dependent release of hepatocyte growth factor and interleukin-1 receptor antagonist from human blood granulocytes and monocytes: evidence for the involvement of plasma IgG, complement C3 and β2 integrin. Inflamm. Res. (2004) 53:277-283.
88. TAHARA Y, IDO A, YAMAMOTO S, MIYATA Y, UTO H, HORI T: Hepatocyte growth factor facilitates colonic mucosal repair in experimental ulcerative colitis in rats. J. Pharmacol. Exp. Ther. (2003) 307:146-151.
89. SAWADA K, MUTO T, SHIMOYAMA T et al.: Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis colum. Curr. Pharm. Des. (1997) 9:307-321.
90. SHIROKAZE J: Leukocytapheresis using a leukocyte removal filter. Ther. Apher. (2002) 6:261-266.
91. SAWADA K, OHNISHI K, FUKUI S: Leukocytapheresis therapy performed with leukocyte removal filter for inflammatory bowel disease. J. Gastroenterol. (1995) 30:322-329.
92. SAWADA K, KUSUGAMI K, SUZUKI Y et al.: Leukocytapheresis in ulcerative colitis: results of a multicenter double-blind prospective case-control study with sham apheresis as placebo treatment. Am. J. Gastroenterol. (2005) 100:1362-1369.
93. SAWADA K, EGASHIRA A, OHNISHI K, FUKUNAGA K, KASUKA T, SHIMOYAMA T: Leukocytapheresis (LCAP) for management of fulminant ulcerative colitis with toxic megacolon. Dig. Dis. Sci. (2005) 50:767-773.
94. SAWADA K, MUTO T, SHIMOYAMA T: Leukocytapheresis with leukocyte removal filter as new therapy for ulcerative colitis. Ther. Apher. (1997) 1:207-211.
95. YAMAJI K, YANG K, TSUDA H, HASHIMOTO H: Fluctuations in the peripheral blood leukocyte and platelet counts in leukocytapheresis in healthy volunteers. Ther. Apher. (2002) 6:402-412.
96. SHIBATA H, KURIYAMA T, YAMAWAKI N: Cellsorba. Ther. Apher. Dial. (2003) 7:44-47.
97. KING C, ILIC A, KOELSCH K, SARVETNICK N: Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell (2004) 117:265-277. •• Based on the findings of these authors, an intervention that induces lymphopenia potentially may trigger homeostatic T cell expansion-associated autoimmune disease.
98. SLEASMAN JW: The association between immunodeficiency and the development of autoimmune disease. Adv. Dent. Res. (1996) 10:57-61. •• See [97].
99. NOGUCHI M, HIWATASHI N, HAYAKAWA T, TOYOTA T: Leukocyte removal filter-passed lymphocytes produce large amounts of interleukin-4 in immunotherapy for inflammatory bowel disease: role of bystander suppression. Ther. Apher. (1998) 2:109-114.
100. ANDOH A, TSUJIKAWA T, INATOMI O et al.: Leukocytaoheresis therapy modulates circulating T cell subsets in patients with ulcerative colitis. Ther. Apher. Dial. (2005) 9:270-279.
101. BRESNIHAN B, CUNNANE G: Infection complications associated with the use of biologic agents. Rheum. Dis. Clin. North Am. (2003) 29:185-202.
102. EGAN LJ, SANDBORN WJ: Advances in the treatment of Crohn's disease. Gastroenterology (2004) 126:1574-1581.
103. SHAND A, FORBES A: Potential therapeutic role for cytokine or adhesion molecule manipulation in Crohn's disease: in the shadow of infliximab? Int. J. Colorectal Dis. (2003) 18:1-11.
104. CAMPBELL DJ, DEBES GF, JOHNSTON B, WILSON E, BUTCHER EC: Targeting T cell responses by selective chemokine receptor expression. Semin. Immunol. (2003) 15:277-286.
105. MACKAY CR, MARSTON WL, DUDLER L: Naïve and memory T cells show distinct pathways of lymphocyte recirculation. J. Exp. Med. (1990) 171:801-817.
106. OLSZEWSKI WL: The lymphatic system in body homeostasis: physiological conditions. Lymphat. Res. Biol. (2003) 1:11-21.
107. BROMLEY SK, THOMAS SY, LUSTER AD: Chemokine receptor CCR7 guides T cell exit from peripheral tissues and entry into afferent lymphatics. Nat. Immunol. (2005) 6:895-901.
108. DEBES GF, ARNOLD CN, YOUNG AJ et al.: Chemokine receptor CCR7 required for T lymphocyte exit from peripheral tissues. Nat. Immunol. (2005) 6:889-894.
109. KLONOWSKI KD: Dynamics of blood-borne CD8 memory T cell migration in vivo. Immunity (2004) 20:551-562.
110. LEE A, WHYTE M, HASLETT C: Inhibition of apoptosis and prolongation of neutrophil functional longevity by inflammatory mediators. J. Leukoc. Biol. (1993) 54:283-288.